← Back to Search

Antifibrinolytic Agent

Tranexamic Acid for Surgical Bleeding Control

Phase 4
Waitlist Available
Led By Brian Kinard, DMD, MD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Bimaxillary orthognathic surgery completed at UAB Highlands Hospital
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will compare the need for DHA when TXA is administered during orthognathic surgery. DHA has risks, so it may be safer to avoid it if TXA can control blood loss and provide good surgical site visualization.

Who is the study for?
This trial is for individuals undergoing bimaxillary orthognathic surgery at UAB Highlands Hospital. It's not suitable for those with high blood pressure, heart issues, bleeding disorders, or who can't safely receive tranexamic acid (TXA).Check my eligibility
What is being tested?
The study is testing if using TXA during jaw surgery can control blood loss well enough to avoid the need for deliberately lowering blood pressure—anesthesia practice that reduces bleeding but has risks like kidney and heart problems.See study design
What are the potential side effects?
While the summary doesn't specify side effects of TXA, common ones include nausea, vomiting, diarrhea. Risks related to avoiding hypotensive anesthesia might include increased bleeding compared to standard practices.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had jaw surgery at UAB Highlands Hospital.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Estimated Blood Loss
Mean Arterial Pressure
Surgeon's Analysis of Surgical Field Visualization

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients Receiving Tranexamic Acid with Avoidance of Hypotensive AnesthesiaExperimental Treatment2 Interventions

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,565 Previous Clinical Trials
2,268,308 Total Patients Enrolled
Brian Kinard, DMD, MDPrincipal InvestigatorUniversity of Alabama at Birmingham

Media Library

Tranexamic Acid (Antifibrinolytic Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05474027 — Phase 4
Low Blood Pressure Research Study Groups: Patients Receiving Tranexamic Acid with Avoidance of Hypotensive Anesthesia
Low Blood Pressure Clinical Trial 2023: Tranexamic Acid Highlights & Side Effects. Trial Name: NCT05474027 — Phase 4
Tranexamic Acid (Antifibrinolytic Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05474027 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it still possible to enroll in this research program?

"According to clinicaltrials.gov, this trial has concluded its recruitment process and is no longer actively seeking patients. The initial post was made on December 1st 2022 with the last edit occurring on August 15th 2022. Fortunately, there are presently 129 different medical studies that need new participants."

Answered by AI

Who can sign up for this medical research experiment?

"This study seeks 50 volunteers aged 12 to 75 with hypotension that have had bimaxillary orthognathic surgery at UAB Highlands Hospital."

Answered by AI

Is the age limit for enrollment in this experiment higher than seventy-five years?

"This medical trial is accepting participants who have surpassed the age of 12 and are below 75 years old."

Answered by AI

Has the FDA endorsed TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION?

"Owing to the Phase 4 status of TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION and its approval for use, our team has assigned it a 3 on their safety scale."

Answered by AI
~28 spots leftby Dec 2025